請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85206完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳小梨(Show-Li Chen) | |
| dc.contributor.author | Hsin-Tung Yeo | en |
| dc.contributor.author | 姚欣彤 | zh_TW |
| dc.date.accessioned | 2023-03-19T22:50:12Z | - |
| dc.date.copyright | 2022-10-03 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-08-04 | |
| dc.identifier.citation | Abmayr, S.M., and Pavlath, G.K. (2012). Myoblast fusion: lessons from flies and mice. Development 139, 641-656. Almada, A.E., and Wagers, A.J. (2016). Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nature Reviews Molecular Cell Biology 17, 267-279. Andrés-Benito, P., Moreno, J., Aso, E., Povedano, M., and Ferrer, I. (2017). Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration. Aging (Albany NY) 9, 823-851. Apel, E.D., Roberds, S.L., Campbell, K.P., and Merlie, J.P. (1995). Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron 15, 115-126. Bähler, M., and Rhoads, A. (2002). Calmodulin signaling via the IQ motif. FEBS Lett 513, 107-113. Barik, A., Xiong, W.-C., and Mei, L. (2012). MuSK: A Kinase Critical for the Formation and Maintenance of the Neuromuscular Junction. In (Humana Press), pp. 203-217. Berkes, C.A., and Tapscott, S.J. (2005). MyoD and the transcriptional control of myogenesis. Seminars in Cell & Developmental Biology 16, 585-595. Biferi, M.G., Cohen-Tannoudji, M., Cappelletto, A., Giroux, B., Roda, M., Astord, S., Marais, T., Bos, C., Voit, T., Ferry, A., et al. (2017). A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Molecular Therapy 25, 2038-2052. Bradley, W.G. (2009). Updates on amyotrophic lateral sclerosis: improving patient care. Ann Neurol 65 Suppl 1, S1-2. Brasil, A.A., Magalhães, R.S.S., De Carvalho, M.D.C., Paiva, I., Gerhardt, E., Pereira, M.D., Outeiro, T.F., and Eleutherio, E.C.A. (2018). Implications of fALS Mutations on Sod1 Function and Oligomerization in Cell Models. Mol Neurobiol 55, 5269-5281. Burden, S.J., Huijbers, M.G., and Remedio, L. (2018). Fundamental Molecules and Mechanisms for Forming and Maintaining Neuromuscular Synapses. Int J Mol Sci 19, 490. Calabria, E., Ciciliot, S., Moretti, I., Garcia, M., Picard, A., Dyar, K.A., Pallafacchina, G., Tothova, J., Schiaffino, S., and Murgia, M. (2009). NFAT isoforms control activity-dependent muscle fiber type specification. Proc Natl Acad Sci U S A 106, 13335-13340. Calderón, J.C., Bolaños, P., and Caputo, C. (2014). The excitation-contraction coupling mechanism in skeletal muscle. Biophys Rev 6, 133-160. Cappello, V., and Francolini, M. (2017). Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis. Int J Mol Sci 18, 2092. Chang, S.W., Tsao, Y.P., Lin, C.Y., and Chen, S.L. (2011). NRIP, a novel calmodulin binding protein, activates calcineurin to dephosphorylate human papillomavirus E2 protein. J Virol 85, 6750-6763. Chen, B., You, W., Wang, Y., and Shan, T. (2020). The regulatory role of Myomaker and Myomixer–Myomerger–Minion in muscle development and regeneration. Cellular and Molecular Life Sciences 77, 1551-1569. Chen, H.H., Chen, W.P., Yan, W.L., Huang, Y.C., Chang, S.W., Fu, W.M., Su, M.J., Yu, I.S., Tsai, T.C., Yan, Y.T., et al. (2015). NRIP is newly identified as a Z-disc protein, activating calmodulin signaling for skeletal muscle contraction and regeneration. J Cell Sci 128, 4196-4209. Chen, H.H., Fan, P., Chang, S.W., Tsao, Y.P., Huang, H.P., and Chen, S.L. (2017). NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer. Oncotarget 8, 21501-21515. Chen, H.H., Tsai, L.K., Liao, K.Y., Wu, T.C., Huang, Y.H., Huang, Y.C., Chang, S.W., Wang, P.Y., Tsao, Y.P., and Chen, S.L. (2018). Muscle-restricted nuclear receptor interaction protein knockout causes motor neuron degeneration through down-regulation of myogenin at the neuromuscular junction. J Cachexia Sarcopenia Muscle 9, 771-785. Chen, P.H., Tsao, Y.P., Wang, C.C., and Chen, S.L. (2008). Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res 36, 51-66. Chen, S., Sayana, P., Zhang, X., and Le, W. (2013). Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 8, 28-28. Cheung, C.L., Chan, B.Y., Chan, V., Ikegawa, S., Kou, I., Ngai, H., Smith, D., Luk, K.D., Huang, Q.Y., Mori, S., et al. (2009). Pre-B-cell leukemia homeobox 1 (PBX1) shows functional and possible genetic association with bone mineral density variation. Hum Mol Genet 18, 679-687. Chin, E.R., Olson, E.N., Richardson, J.A., Yang, Q., Humphries, C., Shelton, J.M., Wu, H., Zhu, W., Bassel-Duby, R., and Williams, R.S. (1998). A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 12, 2499-2509. Cho, H., and Shukla, S. (2020). Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis. Pharmaceuticals 14, 29. Choe, G., Hoang, N.V., and Lee, J.Y. (2020). An Optimized Protocol of Laser Capture Microdissection for Tissue-Specific RNA Profiling in a Radish Tap Root. STAR Protoc 1, 100110. Chou, H.J., Lai, D.M., Huang, C.W., McLennan, I.S., Wang, H.D., and Wang, P.Y. (2013). BMP4 is a peripherally-derived factor for motor neurons and attenuates glutamate-induced excitotoxicity in vitro. PLoS One 8, e58441. Cleveland, D.W., and Rothstein, J.D. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2, 806-819. Deng, H.X., Hentati, A., Tainer, J.A., Iqbal, Z., Cayabyab, A., Hung, W.Y., Getzoff, E.D., Hu, P., Herzfeldt, B., Roos, R.P., et al. (1993). Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261, 1047-1051. Ding, J., Yao, Y., Li, J., Duan, Y., Nakkala, J.R., Feng, X., Cao, W., Wang, Y., Hong, L., Shen, L., et al. (2020). A Reactive Oxygen Species Scavenging and O(2) Generating Injectable Hydrogel for Myocardial Infarction Treatment In vivo. Small 16, e2005038. Ding, Q., Kesavan, K., Lee, K.M., Wimberger, E., Robertson, T., Gill, M., Power, D., Chang, J., Fard, A.T., Mar, J.C., et al. (2022). Impaired signaling for neuromuscular synaptic maintenance is a feature of Motor Neuron Disease. Acta Neuropathologica Communications 10. Dion, P.A., Daoud, H., and Rouleau, G.A. (2009). Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nature Reviews Genetics 10, 769-782. Dobbins, G.C., Luo, S., Yang, Z., Xiong, W.C., and Mei, L. (2008a). alpha-Actinin interacts with rapsyn in agrin-stimulated AChR clustering. Mol Brain 1, 18. Dobbins, G.C., Luo, S., Yang, Z., Xiong, W.C., and Mei, L. (2008b). alpha-Actinin interacts with rapsyn in agrin-stimulated AChR clustering. Mol Brain 1, 18-18. Dominguez, R., and Holmes, K.C. (2011). Actin structure and function. Annu Rev Biophys 40, 169-186. Dupuis, L., and Echaniz-Laguna, A. (2010). Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments. Curr Drug Targets 11, 1250-1261. Dupuis, L., and Loeffler, J.P. (2009). Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr Opin Pharmacol 9, 341-346. Ehlers, M.L., Celona, B., and Black, B.L. (2014). NFATc1 controls skeletal muscle fiber type and is a negative regulator of MyoD activity. Cell Rep 8, 1639-1648. Ehret, G.B., O'Connor, A.A., Weder, A., Cooper, R.S., and Chakravarti, A. (2009). Follow-up of a major linkage peak on chromosome 1 reveals suggestive QTLs associated with essential hypertension: GenNet study. Eur J Hum Genet 17, 1650-1657. Eilers, W., Gevers, W., Van Overbeek, D., De Haan, A., Jaspers, R.T., Hilbers, P.A., Van Riel, N., and Flück, M. (2014). Muscle-Type Specific Autophosphorylation of CaMKII Isoforms after Paced Contractions. BioMed Research International 2014, 1-20. Farrar, M.A., and Kiernan, M.C. (2015). The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics 12, 290-302. Ferraro, E., Molinari, F., and Berghella, L. (2012). Molecular control of neuromuscular junction development. Journal of Cachexia, Sarcopenia and Muscle 3, 13-23. Flück, M., Waxham, M.N., Hamilton, M.T., and Booth, F.W. (2000). Skeletal muscle Ca2+-independent kinase activity increases during either hypertrophy or running. Journal of Applied Physiology 88, 352-358. Funakoshi, H., Belluardo, N., Arenas, E., Yamamoto, Y., Casabona, A., Persson, H., and Ibáñez, C.F. (1995). Muscle-derived neurotrophin-4 as an activity-dependent trophic signal for adult motor neurons. Science 268, 1495-1499. Gillespie, S.K.H., Balasubramanian, S., Fung, E.T., and Huganir, R.L. (1996). Rapsyn Clusters and Activates the Synapse-Specific Receptor Tyrosine Kinase MuSK. Neuron 16, 953-962. Glaser, J., and Suzuki, M. (2018). Skeletal Muscle Fiber Types in Neuromuscular Diseases. In (InTech). Gurney Mark, E., Pu, H., Chiu Arlene, Y., Dal Canto Mauro, C., Polchow Cynthia, Y., Alexander Denise, D., Caliendo, J., Hentati, A., Kwon Young, W., Deng, H.-X., et al. (1994). Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation. Science 264, 1772-1775. Gurney, M.E. (1997). Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 244 Suppl 2, S15-20. Hallock, P.T., Xu, C.F., Park, T.J., Neubert, T.A., Curran, T., and Burden, S.J. (2010). Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. Genes Dev 24, 2451-2461. Han, C.P., Lee, M.Y., Tzeng, S.L., Yao, C.C., Wang, P.H., Cheng, Y.W., Chen, S.L., Wu, T.S., Tyan, Y.S., and Kok, L.F. (2008). Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res 27, 25. Harridge, S.D. (2007). Plasticity of human skeletal muscle: gene expression to in vivo function. Exp Physiol 92, 783-797. Hughes, S.M., Chi, M.M.Y., Lowry, O.H., and Gundersen, K. (1999). Myogenin Induces a Shift of Enzyme Activity from Glycolytic to Oxidative Metabolism in Muscles of Transgenic Mice. Journal of Cell Biology 145, 633-642. Indo, H.P., Yen, H.C., Nakanishi, I., Matsumoto, K., Tamura, M., Nagano, Y., Matsui, H., Gusev, O., Cornette, R., Okuda, T., et al. (2015). A mitochondrial superoxide theory for oxidative stress diseases and aging. J Clin Biochem Nutr 56, 1-7. Inokuchi, Y., Imai, S., Nakajima, Y., Shimazawa, M., Aihara, M., Araie, M., and Hara, H. (2009). Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo. J Pharmacol Exp Ther 329, 687-698. Inoue, A., Setoguchi, K., Matsubara, Y., Okada, K., Sato, N., Iwakura, Y., Higuchi, O., and Yamanashi, Y. (2009a). Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. Sci Signal 2, ra7. Inoue, A., Setoguchi, K., Matsubara, Y., Okada, K., Sato, N., Iwakura, Y., Higuchi, O., and Yamanashi, Y. (2009b). Dok-7 Activates the Muscle Receptor Kinase MuSK and Shapes Synapse Formation. Science Signaling 2, ra7-ra7. Jaiswal, M.K. (2019). Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Medicinal Research Reviews 39, 733-748. Jin, J., Arias, E.E., Chen, J., Harper, J.W., and Walter, J.C. (2006). A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 23, 709-721. Kachalsky, S.G., Aladjem, M., Barchan, D., and Fuchs, S. (1993). The ligand binding domain of the nicotinic acetylcholine receptor. Immunological analysis. FEBS Lett 318, 264-268. Kantor, B., Bailey, R.M., Wimberly, K., Kalburgi, S.N., and Gray, S.J. (2014). Methods for gene transfer to the central nervous system. Adv Genet 87, 125-197. Kim, J.H., Jin, P., Duan, R., and Chen, E.H. (2015). Mechanisms of myoblast fusion during muscle development. Curr Opin Genet Dev 32, 162-170. Knight, L. (2020). Motor neurone disease. InnovAiT: Education and inspiration for general practice 13, 702-711. Kong, X.C., Barzaghi, P., and Ruegg, M.A. (2004). Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 5, 183-188. Krakora, D., Macrander, C., and Suzuki, M. (2012). Neuromuscular Junction Protection for the Potential Treatment of Amyotrophic Lateral Sclerosis. Neurology Research International 2012, 1-8. Kubis, H.-P., Hanke, N., Scheibe, R.J., Meissner, J.D., and Gros, G. (2003). Ca2+ transients activate calcineurin/NFATc1 and initiate fast-to-slow transformation in a primary skeletal muscle culture. American Journal of Physiology-Cell Physiology 285, C56-C63. Liu, J., Campagna, J., John, V., Damoiseaux, R., Mokhonova, E., Becerra, D., Meng, H., McNally, E.M., Pyle, A.D., Kramerova, I., et al. (2020). A Small-Molecule Approach to Restore a Slow-Oxidative Phenotype and Defective CaMKIIβ Signaling in Limb Girdle Muscular Dystrophy. Cell Rep Med 1, 100122. Martínez-Martínez, P., Phernambucq, M., Steinbusch, L., Schaeffer, L., Berrih-Aknin, S., Duimel, H., Frederik, P., Molenaar, P., De Baets, M.H., and Losen, M. (2009). Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. Neurobiology of Disease 35, 14-23. McCord, J.M., and Fridovich, I. (1969). Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244, 6049-6055. McCullagh, K.J., Calabria, E., Pallafacchina, G., Ciciliot, S., Serrano, A.L., Argentini, C., Kalhovde, J.M., Lømo, T., and Schiaffino, S. (2004). NFAT is a nerve activity sensor in skeletal muscle and controls activity-dependent myosin switching. Proc Natl Acad Sci U S A 101, 10590-10595. McDermott, C.J., and Shaw, P.J. (2008). Diagnosis and management of motor neurone disease. Bmj 336, 658-662. Meissner, J.D., Umeda, P.K., Chang, K.-C., Gros, G., and Scheibe, R.J. (2007). Activation of the β myosin heavy chain promoter by MEF-2D, MyoD, p300, and the calcineurin/NFATc1 pathway. Journal of Cellular Physiology 211, 138-148. Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine 377, 1713-1722. Miyoshi, S., Tezuka, T., Arimura, S., Tomono, T., Okada, T., and Yamanashi, Y. (2017). DOK 7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Molecular Medicine 9, 880-889. Moresi, V., Williams, A.H., Meadows, E., Flynn, J.M., Potthoff, M.J., McAnally, J., Shelton, J.M., Backs, J., Klein, W.H., Richardson, J.A., et al. (2010). Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 143, 35-45. Nakano, K., Miki, Y., Hata, S., Ebata, A., Takagi, K., McNamara, K.M., Sakurai, M., Masuda, M., Hirakawa, H., Ishida, T., et al. (2013). Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer. Anticancer Res 33, 4811-4819. Okada, K., Inoue, A., Okada, M., Murata, Y., Kakuta, S., Jigami, T., Kubo, S., Shiraishi, H., Eguchi, K., Motomura, M., et al. (2006). The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312, 1802-1805. Park, K.H.J., Franciosi, S., and Leavitt, B.R. (2013). Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nature Communications 4. Pasinelli, P., and Brown, R.H. (2006). Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7, 710-723. Pattali, R., Mou, Y., and Li, X.-J. (2019). AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Therapy 26, 287-295. Pérez-García, M.J., and Burden, S.J. (2012). Increasing MuSK activity delays denervation and improves motor function in ALS mice. Cell Rep 2, 497-502. Posey, A.D., Jr., Demonbreun, A., and McNally, E.M. (2011). Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol 96, 203-230. Renton, Alan E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J.R., Schymick, Jennifer C., Laaksovirta, H., van Swieten, John C., Myllykangas, L., et al. (2011). A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron 72, 257-268. Richardson, B.E., Beckett, K., Nowak, S.J., and Baylies, M.K. (2007). SCAR/WAVE and Arp2/3 are crucial for cytoskeletal remodeling at the site of myoblast fusion. Development 134, 4357-4367. Román, G.C. (1996). Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. J Neurol Neurosurg Psychiatry 61, 131-137. Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J.P., Deng, H.X., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. Rothstein, J.D. (2009). Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Annals of Neurology 65, S3-S9. Rowland, L.P., and Shneider, N.A. (2001). Amyotrophic lateral sclerosis. N Engl J Med 344, 1688-1700. Sandmann, T., Jensen, L.J., Jakobsen, J.S., Karzynski, M.M., Eichenlaub, M.P., Bork, P., and Furlong, E.E. (2006). A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development. Dev Cell 10, 797-807. Schiaffino, S., Sandri, M., and Murgia, M. (2007). Activity-Dependent Signaling Pathways Controlling Muscle Diversity and Plasticity. Physiology 22, 269-278. Seijffers, R., Zhang, J., Matthews, J.C., Chen, A., Tamrazian, E., Babaniyi, O., Selig, M., Hynynen, M., Woolf, C.J., and Brown, R.H., Jr. (2014). ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation. Proc Natl Acad Sci U S A 111, 1622-1627. Sens, K.L., Zhang, S., Jin, P., Duan, R., Zhang, G., Luo, F., Parachini, L., and Chen, E.H. (2010). An invasive podosome-like structure promotes fusion pore formation during myoblast fusion. Journal of Cell Biology 191, 1013-1027. Shi, Y., Li, Z., Xu, Q., Wang, T., Li, T., Shen, J., Zhang, F., Chen, J., Zhou, G., Ji, W., et al. (2011). Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet 43, 1224-1227. Simon, N.G., Huynh, W., Vucic, S., Talbot, K., and Kiernan, M.C. (2015). Motor neuron disease: current management and future prospects. Intern Med J 45, 1005-1013. Skinnider, M.A., Scott, N.E., Prudova, A., Kerr, C.H., Stoynov, N., Stacey, R.G., Chan, Q.W.T., Rattray, D., Gsponer, J., and Foster, L.J. (2021). An atlas of protein-protein interactions across mouse tissues. Cell 184, 4073-4089.e4017. Stoica, L., Todeasa, S.H., Cabrera, G.T., Salameh, J.S., ElMallah, M.K., Mueller, C., Brown, R.H., Jr., and Sena-Esteves, M. (2016). Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 79, 687-700. Stupka, N., Schertzer, J.D., Bassel-Duby, R., Olson, E.N., and Lynch, G.S. (2008). Stimulation of calcineurin Aα activity attenuates muscle pathophysiology in mdx dystrophic mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 294, R983-R992. Taniguchi, M., Kurahashi, H., Noguchi, S., Fukudome, T., Okinaga, T., Tsukahara, T., Tajima, Y., Ozono, K., Nishino, I., Nonaka, I., et al. (2006). Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies. Hum Mol Genet 15, 1279-1289. Tsai, L.K., Chen, I.H., Chao, C.C., Hsueh, H.W., Chen, H.H., Huang, Y.H., Weng, R.W., Lai, T.Y., Tsai, Y.C., Tsao, Y.P., et al. (2021). Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis. Journal of Cachexia, Sarcopenia and Muscle 12, 665-676. Tsai, T.-C., Lee, Y.-L., Hsiao, W.-C., Tsao, Y.-P., and Chen, S.-L. (2005a). NRIP, a Novel Nuclear Receptor Interaction Protein, Enhances the Transcriptional Activity of Nuclear Receptors*. Journal of Biological Chemistry 280, 20000-20009. Tsai, T.C., Lee, Y.L., Hsiao, W.C., Tsao, Y.P., and Chen, S.L. (2005b). NRIP, a novel nuclear receptor interaction protein, enhances the transcriptional activity of nuclear receptors. J Biol Chem 280, 20000-20009. Tu, P.H., Raju, P., Robinson, K.A., Gurney, M.E., Trojanowski, J.Q., and Lee, V.M. (1996). Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A 93, 3155-3160. Urbani, A., and Belluzzi, O. (2000). Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 12, 3567-3574. Vilmont, V., Cadot, B., Vezin, E., Le Grand, F., and Gomes, E.R. (2016). Dynein disruption perturbs post-synaptic components and contributes to impaired MuSK clustering at the NMJ: implication in ALS. Scientific Reports 6, 27804. Wu, H., Xiong, W.C., and Mei, L. (2010). To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137, 1017-1033. Yang, K.-C., Chuang, K.-W., Yen, W.-S., Lin, S.-Y., Chen, H.-H., Chang, S.-W., Lin, Y.-S., Wu, W.-L., Tsao, Y.-P., Chen, W.-P., et al. (2019). Deficiency of nuclear receptor interaction protein leads to cardiomyopathy by disrupting sarcomere structure and mitochondrial respiration. Journal of Molecular and Cellular Cardiology 137, 9-24. Zammit, P.S. (2017). Function of the myogenic regulatory factors Myf5, MyoD, Myogenin and MRF4 in skeletal muscle, satellite cells and regenerative myogenesis. Semin Cell Dev Biol 72, 19-32. Zhang, Y., Ye, J., Chen, D., Zhao, X., Xiao, X., Tai, S., Yang, W., and Zhu, D. (2006). Differential expression profiling between the relative normal and dystrophic muscle tissues from the same LGMD patient. J Transl Med 4, 53. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16, 1073-1080. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85206 | - |
| dc.description.abstract | 核受體相互作用蛋白 (Nuclear interaction protein, NRIP) 也被稱爲DCAF6或是IQWD1含有860個氨基酸，其中包括了一個IQ motif 以及七個WD40 domain。我們先前的研究表示缺乏NRIP的全身性NRIP基因剔除小鼠會有肌肉無力、慢速肌凝蛋白 (slow myosin) 表現與肌肉收縮力下降以及在施打心臟毒素 (cardiotoxin) 後導致的肌肉損傷組織中有延遲的肌肉再生能力。除此之外，在肌肉NRIP基因剔除小鼠中在第6週時有異常的肌肉運動能，而在第16週時伴隨著神經肌肉接合處 (neuromuscular junction, NMJ) 異常、成肌素 (myogenin) 的下降與運動神經元 (motor neuron) 的退化。我們發現肌肉NRIP基因剔除小鼠的病徵與運動神經元疾病 (motor neuron diseases, MNDs) 相似，我們並推斷此小鼠可以成為MND的模型。因此,我們在MND中選擇了最常見的肌萎縮側索硬化症(Amyotrophic lateral sclerosis, ALS) 進行研究。我們則使用了ALS小鼠模型 (SOD1 G93A轉基因小鼠) 作為我們的NRIP治療對象。我們在先前研究發現在SOD1 G93A 小鼠中進行AAV-NRIP肌肉內註射後可以有效改善運動神經元與NMJ 數量、肌肉神經支配能力 (muscle innervation)、肌肉功能以及神經傳遞能力。這些治療結果顯示 AAV-NRIP基因治療有機會成爲ALS 疾病的治療物之一。因此在這次的研究中我們探討AAV-NRIP 如何在SOD1 G93A小鼠中實現上述的改善。 首先，NRIP已經被證明為一種可以促進肌肉細胞融合 (myoblast fusion) 的肌動蛋白 (actin) 結合蛋白。因此，我們探討了AAV-NRIP 治療後SOD1 G93A小鼠是否透過NRIP有促進myoblast fusion的功能而有肌纖維增大的現象，進而導致運動功能的改善。結果，我們通過免疫熒光分析 (Immunofluorescent assay, IFA) 觀察到AAV-NRIP 治療後的SOD1 G93A小鼠中的肌纖維大小有明顯地增加。這表示NRIP 可以通過其actin結合-myoblast fusion能力促進肌纖維增大。 此外，NRIP還可以在鈣例子的伴隨下與鈣調蛋白 (calmodulin，CaM) 結合以激活 CaN-NFATc1 和 CaMKII 途徑，而這些途徑的活化會進而促進slow myosin基因的表達。我們透過IFA探討AAV-NRIP治療後的SOD1 G93A小鼠中slow myosin表現量。我們發現 AAV-NRIP可以直接增加小鼠的slow myosin表現量以及肌纖維大小。因此這證明了NRIP能夠藉由與CaM的相互作用來增加slow myosin的表現量以達到持續性肌肉收縮能力。 NRIP能夠直接與AChR進行相互作用並穩定位於NMJ的乙醯膽堿受體 (AChR) 複合物。此複合物内含有NRIP，AChR，受體相連突觸蛋白 (rapsyn)以及輔肌動蛋白異構體 (ACTN2)。進而，我們使用了BTX-pulldown分析來研究AChR複合物之間的結合親和力是否可以通過AAV-NRIP的治療後被改善再而影響神經傳遞能力。我們的結果顯示在NRIP蛋白量下降的狀況下，SOD1 G93A 小鼠中的 AChR複合物之間的結合親和力也會降低，這證明了NRIP的缺失會擾亂NMJ的穩定性。不過，在AAV-NRIP治療後的SOD1 G93A小鼠中發現AChR複合物中只有NRIP以及AChR (而非ACTN2以及rapsyn) 之間的相互作用有被改善的現象。 此外，NRIP也可以調節myogenin的轉錄活性進而改善motor neuron的存活以及muscle innervation的能力，因此我們通過共聚焦成像評估了突觸核(synaptic nuclei)中myogenin的表現量。結果我們發現 AAV-NRIP 治療後 SOD1 G93A小鼠NMJ中的myogenin表現量有明顯增加的現象，這也表示了NRIP的確可以上調myogenin表現量以改善motor neuron的存活以及muscle innervation的能力。 總體而言，AAV-NRIP很有機會能夠成爲 ALS的治療藥物，因為NRIP可以藉由與actin結合-myoblast fusion的功能促進肌纖維增大，透過與鈣離子-CaM結合來活化下游CaN-NFATc1 途經來增加slow myosin表現量，以及上調NMJ 中的myogenin轉錄激活(transcriptional activation)。此外，NRIP的下降可能會導致 AChR 複合物之間的結合親和力降低並進而導致神經傳遞能力的降低。 | zh_TW |
| dc.description.abstract | Nuclear interaction protein (NRIP), which is also named DCAF6 or IQWD1 consists of 860 amino acids including one IQ motif and seven WD40 domains. Our previous studies showed that the NRIP deficiency in NRIP global knockout (NRIP gKO) mice would cause muscle weakness, reduced slow myosin expression, and muscle contraction with impaired muscle regeneration ability after cardiotoxin injury. On the other hand, muscle-specific NRIP knockout (NRIP cKO) mice show abnormal muscle function at the age of 6 weeks with abnormal NMJ structure, decreased myogenin levels, motor neuron degeneration, and motor defects at the age of 16 weeks. As the NRIP cKO mice disease phenotypes are found to resemble those of motor neuron diseases (MNDs), we hypothesized that it could be a model of MND. Hence, amyotrophic lateral sclerosis (ALS) is chosen among the MNDs for investigation and we used the ALS mouse model (SOD1 G93A transgenic mouse) as our NRIP-treating target. Previously, we found that the intramuscular injected AAV-NRIP in SOD1 G93A mice could improve the motor neuron, NMJ number, muscle innervation, muscle functions, and neurotransmission activity. These indicated that AAV-NRIP could be a potential therapeutic agent for ALS disease. In this study, we continuously investigated how AAV-NRIP could achieve these improvements in SOD1 G93A mice. First, NRIP is shown to be an actin-binding protein that could initiate myoblast fusion. Thus, we would like to discover if the increased motor function in AAV-NRIP treated SOD1 G93A mice was improved by the increase of myofiber size through myoblast fusion. As a result, we observed an increase in the myofiber size of soleus muscle from SOD1 G93A mice by AAV-NRIP treatment via performing the immunofluorescent analysis (IFA). This indicated that NRIP could increase myofiber size through its actin-binding-dependent myoblast fusion ability. Next, NRIP could also bind with calmodulin under the presence of calcium to activate CaN-NFATc1 and CaMKII pathways which might further induce slow myosin gene expressions. Thus, we further investigated the slow myosin expression level in the soleus of AAV-NRIP treated SOD1 G93A mice through IFA. We found that AAV-NRIP directly rescued the slow myosin expression level along with the increase of slow myosin myofiber size in SOD1 G93A mice. Thereof, NRIP could increase the expression level of slow myosin for continuous muscle contractions through the interaction with calmodulin. Moreover, NRIP could interact with AChR and stabilize the AChR complex (AChR-rapsyn-ACTN2) at the NMJ. Hence, we investigated whether the binding affinity between the NMJ complex could be rescued by AAV-NRIP via performing a BTX-pulldown assay for improved neurotransmission ability. Our results showed that the binding affinity between the AChR complex was reduced in SOD1 G93A under the reduction of NRIP which indicated that the loss of NRIP would disrupt the NMJ stability. However, only the interaction between NRIP and AChR but not ACTN2 and rapsyn was rescued by the AAV-NRIP treatment in SOD1 G93A mice. Furthermore, NRIP could regulate myogenin transcriptional activity, thus we evaluated the myogenin expression in synaptic nuclei which might contribute to the improved motor neuron survival and muscle innervation in AAV-NRIP treated SOD1 G93A mice through confocal imaging. We found that the myogenin expression was increased at the NMJ of AAV-NRIP treated SOD1 G93A mice which indicated that NRIP could upregulate myogenin expression for improved motor neuron survival and muscle innervation. In sum, AAV-NRIP could be a potential therapeutic drug for ALS as it increased the myofiber size through actin-binding myoblast fusion, and slow myosin expression levels through the activation of calcium-calmodulin dependent CaN-NFATc1 pathways, and myogenin expression at the NMJ through transcriptional activation. Besides, the reduction of NRIP levels could cause a decreased binding affinity between the AChR complex which might further affect disrupted neurotransmission ability. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T22:50:12Z (GMT). No. of bitstreams: 1 U0001-0308202212221900.pdf: 2473305 bytes, checksum: 70fe90f8ac95b93c740efb0be9adeba2 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 口試委員會審定書 I 致謝 II 中文摘要 III Abstract V Table of contents VIII Chapter 1 Introduction 1 1.1 The characteristics of NRIP 1 1.2 The mechanism of NRIP-regulated muscle contraction 2 1.3 The role of NRIP in myoblast fusion 6 1.4 The characteristics of the neuromuscular junction (NMJ) 7 1.5 The role of NRIP in the neuromuscular junction 9 1.6 The role of NRIP for myogenin regulation 10 1.7 Neuromuscular junction disorder associated with motor neuron diseases 11 1.8 The characteristics of amyotrophic lateral sclerosis (ALS) 12 1.9 The ALS mouse model, human SOD1 G93A mouse 13 1.10 Gene therapy for motor neuron diseases 15 1.11 The findings of NRIP in human ALS patients 17 1.12 Aims of this study 18 Chapter 2 Materials and Methods 21 2.1 Intramuscular injection of SOD1 G93A mice 21 2.2 Biotin-BTX pulldown assay 21 2.3 Western blot analysis 22 2.4 Tissue isolation and frozen section preparation 23 2.5 Immunofluorescence assay of extracellular matrix (laminin), slow myosin, and exogenous FLAG-NRIP in skeletal muscle 23 2.6 Immunofluorescence assay of myogenin expression in synaptic region nuclei of skeletal muscle 24 2.7 Statistical analysis 25 Chapter 3 RESULTS 26 3.1 AAV-NRIP gene therapy of SOD1 G93A mice can rescue myofiber size. 26 3.2 AAV-NRIP treated SOD1 G93A can rescue slow myosin heavy chain. 29 3.3 The rescued effect of NRIP on the binding affinity of AChR-rapsyn-ACTN2 complex in SOD1 G93A mice. 33 3.4 Evaluation of the myogenin expression at the nuclei of post-synaptic regions in AAV-NRIP treated SOD1 G93A mice at age 17 weeks. 36 Chapter 4 DISCUSSION 38 Chapter 5 FIGURES 48 Chapter 6 APPENDIX 59 Chapter 7 REFERENCES 61 | |
| dc.language.iso | en | |
| dc.subject | 成肌素 | zh_TW |
| dc.subject | AAV-NRIP | zh_TW |
| dc.subject | 肌萎縮側索硬化症 | zh_TW |
| dc.subject | 肌肉細胞融合 | zh_TW |
| dc.subject | 慢速肌凝蛋白 | zh_TW |
| dc.subject | 神經肌肉接合處 | zh_TW |
| dc.subject | 結合親和力 | zh_TW |
| dc.subject | AAV-NRIP | en |
| dc.subject | myogenin | en |
| dc.subject | binding affinity | en |
| dc.subject | NMJ | en |
| dc.subject | slow myosin | en |
| dc.subject | myoblast fusion | en |
| dc.subject | ALS | en |
| dc.title | 探討AAV-NRIP是否可以作爲肌萎縮側索硬化症的治療藥物 | zh_TW |
| dc.title | To study the potential of AAV-NRIP as a therapeutic drug for Amyotrophic Lateral Sclerosis (ALS) | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 曾秀如(Shiou-Ru Tzeng),黃祥博(Hsiang-Po Huang) | |
| dc.subject.keyword | AAV-NRIP,肌萎縮側索硬化症,肌肉細胞融合,慢速肌凝蛋白,神經肌肉接合處,結合親和力,成肌素, | zh_TW |
| dc.subject.keyword | AAV-NRIP,ALS,myoblast fusion,slow myosin,NMJ,binding affinity,myogenin, | en |
| dc.relation.page | 70 | |
| dc.identifier.doi | 10.6342/NTU202202004 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-08-04 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2027-08-03 | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0308202212221900.pdf 未授權公開取用 | 2.42 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。